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Genetic research in sports has a history of more than 40 years of endeavouring to find 
out which genetic factors can predict the performance of an athlete. With increasing 
knowledge of the human genome and availability of genetic testing the market of 
direct-to-consumer genetic tests has exploded in recent years. There are tests for 
genetic variants for medical and general health issues, but there are also ‘lifestyle’ 
tests, including tests for indicators for sport performance. The human gene map for 
fitness and performance includes hundreds of genes that play a role in 
cardiorespiratory endurance, muscle strength, exercise tolerance, body composition 
and energy metabolism. However, there is currently no evidence that genotyping an 
individual is superior to traditional physiological tests in predicting athletic 
performance.  
 
The impact of genetic test results is much higher in certain medical conditions which 
are associated with significant health risks when performing competitive sport. These 
are generally rare inherited disorders, mostly resulting in cardiovascular dysfunction. 
There are major ethical issues as to whether genetic or clinical pre-participation 
screenings should be applied to the population in order to prevent disease or death 
during sport. Some of these issues will be addressed in this article. 
Introduction 
Genetic research in sports medicine and the associated ethical issues have a long 
history. The question is whether predictive clinical or genetic screening is warranted 
in sports medicine. Is there a genetic profile that predicts the makings of a perfect 
athlete which might be used to encourage or discourage participation in specific 
sports? Should we try to gain a better knowledge of and access to molecular genetic 
testing of medical conditions which imply an increased individual health risk when 
performing competitive sports? 
Many genes with low predictability 
If you make a few clicks on the internet you can request a genetic test, using your 
saliva, to determine whether you are a sprinter or a marathon runner, based on a 
variant of the ACTN3 gene.  
 
Hard to believe? Yes, because, like many direct-to-consumer genetic tests, this test 
lacks sensitivity, specificity and positive predictive value. Indeed, it would be a big 
advantage in sports medicine if we were able to find out who has the genetic 
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background to become a perfect athlete. Sports genetics research has a history of more 
than 40 years of trying to determine genetic factors that influence phenotypic traits as 
regards physical performance, training response and the metabolic adaptation of a 
successful athlete. Many studies have focused on the ACTN3 genotype for example, 
i.e. the genetic variations of the skeletal-muscle actin-binding protein α-actinin 3. 
ACTN3 expression is restricted to fast muscle fibres, and the consequence of α-actinin 
3 deficiency should be a reduced sprint performance. Due to a homozygous stop 
codon in ACTN3 (R577X) α-actinin 3 deficiency is common in the general 
population, occurring with a frequency of 25 per cent in Asian and about 18 per cent 
in European populations.2 Following the observation in a relatively small Australian 
study3 that sprint athletes had a lower frequency of the α-actinin 3 null mutation 
compared to controls or endurance athletes, ACTN3 testing has become commercially 
available.  
 
However, subsequent studies including different disciplines and larger numbers of 
probands did not confirm this finding.4 Very similar expectations and observations are 
related to many other genes that are supposed to influence sports performance and are 
annually updated in the Human Fitness Gene Map.5 Hundreds of genes influence 
athletic performance, including those which determine skeletal muscle mass, growth 
and function, dynamic response to training, cardiovascular efficiency, energy 
metabolism, and many other factors. The conclusion after many studies is that with 
the current state of knowledge, the field of genetic influences on sports performance 
remains in its infancy.6 Since single genes have only a very limited impact on athletic 
performance, it is hoped to gather more information by a polygenic approach, i.e. a 
combined analysis of polymorphisms that play a role in either endurance,7 power8 or 
metabolic pathways.9 However, there is still no evidence that any of the identified 
profiles have a substantial predictive value for prospectively identifying potential elite 
athletes. It is unlikely that genetic tests will replace traditional performance tests used 
to assess exercise-related variables such as oxygen uptake, running speed, or strength 
measurements in the near future.10 This has been recently summarised by Pitsiladis 
and Scott: “The current genetic evidence does not warrant genotyping an individual to 
establish the ability to run fast when this trait can be measured far more efficiently 
with a stopwatch.” 11 So far the attempt to redesign training programmes according to 
the individual genetic profile - as introduced, for example, in an Australian rugby 
team named Sea Eagles12 on the basis of 11 exercise-related genes - seems premature 
and not of proven efficacy. 
Rare genes with high predictability 
While most phenotypic traits, either in the context of talent or in the context of disease 
are multifactorial, i.e. caused by many genetic and exogeneous factors, there are rare 
monogenic disorders where competitive sports should be avoided. These are mostly 
conditions affecting the heart muscle or the heart conduction system which may result 
in sudden cardiac death.  
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Sudden cardiac deaths among young athletes have a high impact in the media and are 
often overestimated. The risk as a whole is low, with 2 affected athletes per 100,000 
per year.13, 14 A recent assessment of cardiac arrest among long-distance runners in the 
United States found an incidence rate of 0.54 per 100,000 participants,15 most 
commonly attributed to heart muscle or heart vessel disease.  
 
Italy was the first country in the world to introduce mandatory cardiovascular pre-
participation screening for athletes, including electrocardiographic examinations, in 
1982. That country’s experience has resulted in a common European consensus 
protocol for the prevention of sudden death in young competitive athletes.16 Not all 
European countries agree with this rigid protocol, however.17,18 It has been shown that 
pre-participation screening ECGs can be difficult to interpret. Mistakes in ECG 
interpretation could lead to high rates of inappropriate sports guidance.19 The 
European recommendation is that screenings should start at the beginning of 
competitive activity, should be repeated every two years and include medical history, 
physical examination, and 12-lead electrocardiogram (ECG). It is estimated that under 
this strategy 2 per cent of subjects affected by cardiovascular conditions would be 
disqualified from competitive sports and nearly 90 per cent of sudden cardiac deaths 
prevented20. In the USA, meanwhile, the cost effectiveness of screening with ECG 
plus history and physical examination has been calculated and it has been confirmed 
as the preferred strategy.21 Family history is part of the screening but so far does not 
include genetic testing. There are some conditions for which genetic screening has 
been discussed: 
 
1. Hypertrophic cardiomyopathy (HCM): This is the most frequent among the 
monogenic conditions in this context, affecting 1 in 500 in the population. Due to 
defects in different genes encoding for contractile heart proteins, affected 
individuals develop an increased cardiac muscle mass, often asymmetric, which 
reduces cardiac function and results in cardiac rhythm disturbances over time. Age 
at onset is generally in youth or young adulthood, i.e. an age when athletes have 
the most productive and competitive period. HCM has been reported to be the 
leading cause of sudden death in young competitive athletes, accounting for up to 
40 per cent of athletic field deaths in the USA (but it occurs much less frequently 
in sudden deaths in Italian athletes - 2 per cent).22 The disease is autosomal 
dominantly inherited. This means that the presence of one mutated gene copy of 
the two copies available for most genes causes the disease. The mutated gene copy 
is passed on to the next generation with a statistical probability of 50 per cent. 
HCM shows a high penetrance; this means that nearly all mutation carriers 
develop the disease. If the defective gene copy is known to exist in a family this 
allows predictive genetic testing of persons at risk. Genetic screening in the 
general population is limited by the fact that only 60-70 per cent of the genes 
causing HCM are identified, i.e. it is not possible to exclude a genetic risk in an 
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individual without positive family history. This is only possible if the mutation of 
the affected relative is known and can be excluded in the person at risk. Therefore 
cascade screening of relatives in families with known mutations might be 
advocated. Since HCM can be detected preclinically by echocardiographic or 
electrocardiographic studies before cardiac function is reduced, it is a matter of 
debate as to whether predictive genetic testing is useful, in particular as no 
preventive or specific treatment is available.  
 
2. Inherited cardiac rhythm disturbances: Abnormal cardiac conduction is associated 
with an increased risk for a sudden cardiac death and is caused by a variety of 
genetic syndromes, e.g. long QT (LQT) syndrome, short QT syndrome, Brugada 
syndrome, arrhythmogenic right ventricular cardiomyopathy, Wolff-Parkinson-
White syndrome. In the Italian study this group was responsible for about 30 per 
cent of sudden deaths in athletes.23 Inheritance is also autosomal dominant in most 
families but compared to HCM, the penetrance is incomplete and prediction of 
cardiac complications far from precise. Molecular genetic screening in athletes 
without a medical or family history will also be hampered by a large number of 
genes causing the same disease, so called genetic heterogeneity, and a large 
proportion of unclassified genetic variants which might be of clinical significance 
but can also represent harmless polymorphisms. Following the protocol of the 
European Society of Cardiology24 the consequence of genetic screening would be 
to exclude possible gene carriers from participating in competitive sport without 
being able to specify the overall risk. A negative result of genetic screening, on 
the other hand, does not exclude risk for an inherited heart disease, taking into 
account that many genes remain to be identified and that not all mutations can be 
covered in a testing panel. 
 
Medical intervention in genetic arrhythmia syndromes generally starts when the 
defined ECG abnormalities are detected,25 a time point which cannot be predicted by 
mutation analysis. The risk of serious cardiac events ranges from 50 per cent up to the 
age of 15 years in some mutation types of the KCNQ1 gene causing LQT126 to less 
than a 10 per cent lifetime risk in Brugada syndrome.27 A situation in clinical practice 
might be envisaged as follows: A young athlete has a family history of a cardiac arrest 
in a cousin who has a mutation in the SCN5A gene, which can explain about 20 per 
cent of patients with Brugada syndrome. Given that this mutation has been transmitted 
in the family through several generations without causing trouble (except for the 
cousin) and can also be detected in our athlete, should he be banned from competitive 
sports or not? 
 
Moreover, cardiac events in LQT syndromes are associated with gene-specific 
triggers, in that events in LQT1 are triggered by exercise and so are particularly 
dangerous for athletes, while most events in LQT2 and LQT3 occur during sleep or 
rest. Therefore risk stratification in cardiac rhythm disturbances has to take the 
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specific type of arrhythmia, the cumulative probabilities for adverse events, the 
mutation type and location and the physical activity of an athlete into account.  
Few genes with moderate predictability 
Athletes in high-contact sports, such as boxing, ice-hockey or rugby, have a higher 
risk of brain damage. Following the observation that chronic traumatic brain injury in 
boxing was associated with a 50 per cent increase in rates of Alzheimer’s disease in a 
small sample of boxers,28 a debate began as to whether athletes should undergo 
genetic testing for factors that predispose to Alzheimer’s disease. Rates of 
Alzheimer’s disease increase dramatically with age. While only 1-2 per cent of 
individuals develop the disease between 65 and 70 years, this proportion increases to 
10-20 per cent in the age group between 85 and 90 years.29 The underlying causes of 
the disease are still not fully understood, but it is known that the genetic information 
given by the apolipoprotein E (APOE) gene can influence the risk. The APOE gene is 
present in three variants in the population, ε2, ε3, or ε4. In the presence of one ε4 
copy, the age-related risk of developing Alzheimer’s disease is 3-fold; if both gene 
copies belong to the ε4 variant, this risk is increased to 10-15-fold.30  
 
While one study of college athletes did not show an important association between 
carrying the APOE ε4 variant and sustaining a concussion,31 outcome after head 
injury seems to be influenced by APOE.32 If an athlete with at least one APOE ε4 
gene copy starts a competitive career as a boxer, his individual risk for Alzheimer’s 
disease or a poor outcome after head injury is most likely increased and it might be 
important to advise him in this respect. However, since there is no prevention or 
treatment of Alzheimer’s disease at present, the information about an increased risk 
for late onset dementia in a young athlete might be potentially harmful for his quality 
of life, in terms of medico-legal, employment and insurance issues. As such no 
guidelines exist on how to deal with a possible increased risk for Alzheimer’s disease 
in sports at risk for brain damage, nicely summarised by Alla Katsnelson: “Gene tests 
for brain injury (are) still far from the football field.” 33 
Conclusion 
On the basis of our current knowledge, genetic screening to predict athletic 
performance is not recommended. As long as clinical assessments or traditional 
performance tests are superior, genetic testing should only be permitted at the request 
of the individual who will be tested. Following the guidelines of the European Society 
of Human Genetics (ESHG)34 commercially available tests for genetic variants in the 
context of general health purposes, life-style and sport performance should only be 
offered if the clinical utility and validity of the analysis is proven, if informed consent 
is given, and if privacy and confidentiality are secured. Since genetic results can 
reduce quality of life and can have significant socioeconomic consequences, these 
tests should be confined to mature individuals and the right not-to-know should be 
respected. Special measures should be taken to avoid inappropriate testing of minors. 
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In families at risk for rare monogenic disorders associated with an increased death rate 
in competitive sports, individual decision-making about predictive genetic testing is 
warranted. The German Genetic Diagnosis Act which was introduced in 201035 has 
strict regulations as regards genetic testing, specifically in minors. In the case of 
predictive genetic testing, genetic counselling is mandatory under the Act. Predictive 
genetic testing is allowed in minors only if there are options for prevention or 
treatment or if potential harmful investigations can be avoided. For diseases that start 
in adulthood, genetic tests should be confined to mature individuals who fully 
understand the relevant issues. Similar recommendations were made by the ESHG.36 
Internationally and nationally approved guidelines are required for the implementation 
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